Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Debt (2016 - 2025)

Historic Total Debt for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $132000.0.

  • Pharma's Total Debt fell 222.22% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $132000.0, marking a year-over-year decrease of 222.22%. This contributed to the annual value of $134000.0 for FY2025, which is 218.98% down from last year.
  • Latest data reveals that Pharma reported Total Debt of $132000.0 as of Q3 2025, which was down 222.22% from $133000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Total Debt peaked at $580000.0 during Q1 2021, and registered a low of $132000.0 during Q3 2025.
  • Its 5-year average for Total Debt is $163263.2, with a median of $140000.0 in 2023.
  • Data for Pharma's Total Debt shows a peak YoY increase of 106000.0% (in 2021) and a maximum YoY decrease of 7619.05% (in 2021) over the last 5 years.
  • Pharma's Total Debt (Quarter) stood at $148000.0 in 2021, then decreased by 4.73% to $141000.0 in 2022, then decreased by 2.13% to $138000.0 in 2023, then decreased by 2.9% to $134000.0 in 2024, then fell by 1.49% to $132000.0 in 2025.
  • Its last three reported values are $132000.0 in Q3 2025, $133000.0 for Q2 2025, and $134000.0 during Q1 2025.